The prognostic value of circulating cell-free DNA in breast cancer

Tan, Guoqiang; Chu, Chang; Gui, Xiujuan; Li, Jinyuan; Chen, Qiufang

doi:10.1097/md.0000000000010197

Cited by 40 publications

(34 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While large meta-analyses ( Table 2 ) have confirmed the prognostic relevance of CTCs, the existing data on circulating DNA is much less extensive ( Table 3 ). A meta-analysis published in 2018 by Tan et al included a total of 1127 patients from 10 trials, the majority with non-metastatic disease 22 . Unlike in the pooled analyses on CTC significance, the populations here were markedly smaller (336 patients maximum).…”

Section: Clinical Applications Of Liquid Biopsy In Early Breast Cancementioning

confidence: 99%

See 1 more Smart Citation

Liquid Biopsy in Breast Cancer

Banys‐Paluchowski

Krawczyk

Fehm

2020

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

In recent years, the blood-based analysis of circulating tumour cells (CTCs) and nucleic acids (DNA/RNA), otherwise known as liquid biopsy, has become increasingly important in breast cancer. Numerous trials have already underscored the high prognostic significance of CTC detection in both early and metastatic stages. Moreover, the changes in CTC levels and circulating tumour DNA (ctDNA) during the course of the disease correlate with the response to treatment. Research currently focuses on liquid-biopsy based therapeutic interventions in metastatic breast cancer. In this context, alpelisib, a PI3K inhibitor, was the first agent to be approved by FDA and EMA.

show abstract

Section: Clinical Applications Of Liquid Biopsy In Early Breast Cancementioning

confidence: 99%

“…3 ). In einer 2018 veröffentlichten Metaanalyse von Tan et al wurden insgesamt 1127 Patientinnen aus 10 Studien berücksichtigt, der Großteil im nicht metastasierten Setting 22 . Anders als in den gepoolten Analysen zur Relevanz von CTCs waren hier die Kollektive deutlich kleiner (max.…”

Section: Verbesserung Der Prognoseeinschätzungunclassified

Liquid Biopsy in Breast Cancer

Banys‐Paluchowski

Krawczyk

Fehm

2020

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

show abstract

“…Bettegowda et al [17] reported that ctDNA was detectable in > 75% of patients with advanced breast carcinoma, compared to 50% of those with localized tumors. Recently, a large metaanalysis including 10 studies examined the prognostic relevance of cell-free DNA (cfDNA) in 1127 patients with BC [18] . Six studies examined only patients with early BC (stages I-III, n = 840), two studies included metastatic patients (stage IV, n = 183), and two studies included both groups (stages I-IV, n = 104).…”

Section: Prognosticationmentioning

confidence: 99%

Liquid biopsy in metastatic breast cancer

Banys-Paluchowski¹,

Paluchowski²

2019

CDR

View full text Add to dashboard Cite

The spread of single tumor cells shed by the primary tumor has been observed in most solid carcinomas and is generally associated with poor clinical outcome. Tumor cells detected in the peripheral blood are commonly referred to as circulating tumor cells (CTCs) and are seen as possible precursors of metastatic disease. Beyond CTCs, circulating tumor DNA and non-coding RNA are increasingly the focus of translation cancer research. In metastatic breast cancer (MBC), elevated levels of CTCs have been confirmed as an independent prognostic factor. While detection of elevated counts after the start of systemic therapy predicts poor response, it is unclear which treatment strategy should be offered in the case of CTC persistence. Currently, the main potentials of blood-based diagnostics in BC are therapy monitoring and liquid biopsy-based treatment interventions. Recently, the first positive study on CTC-guided therapy choices in hormone receptor positive HER2 negative MBC was published. In the present review, we discuss the current data and potential clinical application of liquid biopsy in the metastatic setting.

show abstract

“…In addition, the MRI high cost, the long holding up list in developing countries and the inaccurate result of imaging techniques (Kuhl, 2019). So, finding diagnostic biomarkers may be a useful alternative choice (Tan et al 2018).…”

Section: Introductionmentioning

confidence: 99%

Diagnostic role of collagen III in the diagnosis of breast cancer in Egyptian women

Attallah¹,

El‐Far

Sayes³

et al. 2020

Journal of Bioscience and Applied Research

View full text Add to dashboard Cite

Mammography, magnetic resonance imaging (MRI), and ultrasound are useful tools that can be used in breast cancer (BC) screening but these methods have various limitations. Thus, finding diagnostic biomarkers may be a useful alternative choice. A total of 142 females with breast diseases (40 females with benign conditions and 102 females with BC) were included in the study. In addition to age-and sex-matched 29 normal females as a negative control. The level of collagen III was detected using the ELISA technique. It was (21.29±3.14 µg/ml) in sera of females with BC higher than in benign (13.91±2.65 µg/ml) and in normal (5.69±0.43 µg/ml) females. Collagen III yielded an AUC of 0.86 to differentiate BC from normal females and an AUC of 0.62 to differentiate BC females from those with benign conditions. Moreover, AUC was risen to 0.72 to differentiate females with BC from those without BC. While the index provided values that were significantly (P<0.01) higher in BC (9.1±1.3) than benign (6.3±1.1) and normal (2.5±1.1) females. It yielded an AUC of 0.98 (sensitivity = 90.0 %) to differentiate BC from normal females and an AUC of 0.84 to differentiate BC females from those with benign conditions. Moreover, AUC was risen to 0.87 to differentiate females with BC from those without BC (sensitivity = 84.0 %). In conclusion, serum collagen III concentration represents a candidate biomarker for BC. Moreover, its combination with cancer antigen 15-3 (CA 15.3) and age provided a valuable index for BC diagnosis with high accuracy.

show abstract

The prognostic value of circulating cell-free DNA in breast cancer

Cited by 40 publications

References 27 publications

Liquid Biopsy in Breast Cancer

Liquid Biopsy in Breast Cancer

Liquid biopsy in metastatic breast cancer

Diagnostic role of collagen III in the diagnosis of breast cancer in Egyptian women

Contact Info

Product

Resources

About